DIVI S LABORATORIES LTD vs Welcure Drugs & Pharmaceuticals Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Welcure Drugs & Pharmaceuticals Ltd (WELCURE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs WELCURE on 9 of 14 metrics (3 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth· not comparable
  • Size & financial health30
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.08
P/E ratio
11.50
10.62
P/B ratio
0.25
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹0.02

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
-5.50%
22.00%
Return on capital
3.00%
33.00%
EBITDA margin
4.00%
24.32%
Net margin
8.00%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y) even
12.10%
Profit CAGR (3Y) even

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.42L Cr
Market cap
₹30 Cr
₹10,560 Cr
Revenue
₹25 Cr
₹2,568 Cr
Net profit
₹2 Cr
0.00
Debt / equity even
0.00
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Welcure Drugs & Pharmaceuticals Ltd
  • + ["Company has reduced debt.", "Company is almost debt free.", "Stock is trading at 0.28 times its book value"]
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of -2.28% over last 3 years.", "Company has high debtors of 213 days."]
DIVI S LABORATORIES LTD full analysis Welcure Drugs & Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVISLAB vs WELCURE: Share Price, Valuation & Which to Buy | DocStoX